CSE: UDOC | FRA: L7T | OTCQB: UDOCF
Investor
Presentation
Click To
Download
Investor Presentation
Click To
Download
News
Alerts
Click To
Sign Up
News Alerts
Click To
Sign Up

COMPANY

Healthcare is rapidly adopting new technologies.
So are patients.

Since the onset of COVID-19, the global IoMT* market is projected to grow at a CAGR of 15.9% from $39.3 billion in 2020 to $172.4B by 20301 and Telemedicine is expected to exceed $244B by 20322.

* Internet of Medical Things

1 https://www.precedenceresearch.com/internet-of-medical-things-market – Precedence Research

2 https://www.gminsights.com/industry-analysis/telemedicine-market  – Global Market Insights

eHealth Market Demand

eHealth care is still in its infancy in North America and around the world. We’re working to change that. Now with the aid of AI, the opportunity has become even greater.

Two thirds of patients are ready to upgrade to virtual care, with 8% already having tried it.1
North America led the industry in 2022 with 53.3% of total revenue.2

FROM

$ 0 B

TO

$ 0 B
The Global eHealth Market is estimated to grow from USD $102.7B in 2022 to USD $893.7B by 2032.2

FROM

$ 0 B

TO

$ 0 B
In the US alone eHealth Market was valued at USD 8.30 billion in 2019 and expected to reach USD 476.3B billion by 2032.2

1 Telehealth Index: 2019 Consumer Survey

2 https://www.globenewswire.com/en/news-release/2023/04/24/2652922/0/en/Telehealth-Market-to-Hit-Enormous-Growth-of-24-13-By-2032.html – Precedence Research

Artificial Intelligence Market Demand

Artificial Intelligence in eHealth Care is growing rapidly as features & benefits unlock value

The global artificial intelligence market size was valued at $428.00 billion in 20221
AI in Healthcare grew from $11.06B in 2021 to $15.1B in 2022.1, 2
AI can reduce patient wait times and increase identification of false positive results.3

FROM

$ 0 B

TO

$ 0 B
The global AI Market is estimated to grow from USD $515.31B in 2023 to USD $2025.12B in 2030. CAGR 21.6%1

FROM

$ 0 B

TO

$ 0 B
Projected AI in global Healthcare Market is estimated to grow from USD $15.1B in 2022 to USD $187.95B by 2030. CAGR 51.8%1, 2

FROM

0 Days

TO

0 Days
The US national average wait time was 21 days in in 2004. In 2022, the wait time had increased to 26 days.3

1 https://www.fortunebusinessinsights.com/industry-reports/artificial-intelligence-market-100114 – Fortune Business Insights

2 https://www.databridgemarketresearch.com/reports/global-artificial-intelligence-in-healthcare-market – Data Bridge Market Research

3 https://www.statnews.com/2023/05/02/doctor-appointment-wait-times-solutions/#:~:text=That%20year%2C%20the%20national%20average,an%20average%20of%2026%20days – STAT News

0 +
Pharmacies in US
Source Link
0 +

Pharmacies in Canada

Source Link

Market Opportunity

Proposed locations for Unidoc Virtual eHealth Clinics extends beyond traditional pharmacies:

  • Grocery Stores
  • Pharmacies
  • Long-Term Care Facilities
  • Post-Secondary Education Campuses
  • Corporate Offices & More
  • Underserved and Remote Locations

With easy access, contactless visits and informed results, UniDoc aims to offer improved patient reach and growth opportunities.

*https://www.pcmanet.org/wp-content/uploads/2020/03/FINAL_Independent-Pharmacies-in-the-U.S.-are-More-on-the-Rise-than-on-the-Decline.pdf

**https://www.pharmacists.ca/pharmacy-in-canada/pharmacists-in-canada/

We believe there is a need for:

LOCATIONS

Easily accessible.

TIMES

Little to no wait times (pre-book or walk in).

SPECIALIST APPOINTMENTS

Booked immediately.

HIGH QUALITY

Experienced physicians.

RESULTS

Immediate test results.

SMART DIAGNOSIS

AI Powered Instant Triage & Treatment Plan.

PARTNERSHIPS

Medical/Technology

Delivering better patient experiences with devices built to withstand the demands of healthcare environments.

Enabling data-driven healthcare through automating data collection from disparate systems and devices. Our Mission is to be at every ICU bed around the world. Our Vision is to touch 1 billion lives.

For the last 30 years, AMD’s integrated medical devices have established a pioneering and leading role in virtual care technology.

Dedalus is a billion-dollar healthcare company with extensive experience in connected care including hospital IT. Dedalus supports over 5000 hospitals and 4800 laboratories worldwide.

Features AI – driven analytics and assessment tools to provide a deep understanding of population health metrics and access to the entire array of remote telehealth services including 24/7 on demand physicians, mental health, medical weight loss, longitudinal care, and expert medical opinion capabilities.

Redefines interoperability by creating cohesive FHIR-based healthcare data and workflow connectivity and ensures standards-based data exchange across health IT systems for continuity of care, care coordination and patient safety.

Trusted supplier

APEX Building Technology Inc.

With these powerful partnerships, we’re positioning for a leading role in the delivery of advanced eHealth solutions.

Better access to
healthcare is the future.

VIEW INVESTOR INFORMATION

Experienced Leadership

Our cross-functional team has a broad range of skills. We’re bringing this talent together across disciplines to change medicine for the better. Forever.

Management

Antonio Baldassarre

CEO, President and Director

Franco Staino

DIRECTOR

Dr. Sazzad Hossain, PhD

Chief Scientific Officer

Sina Pirooz

Director

Austin Thornberry

CFO & Director

Matt Chatterton

Director

CSE: UDOC | FRA: L7T | OTCQB: UDOCF
Investor Presentation

Subscribe to News Alerts

By submitting the form, you agree to receive communications from UniDoc Health.

Consent*

UniDoc Health Corp. © 2024. All rights reserved.

Antonio Baldassarre

CEO, President and Director

Mr. Baldassarre has held senior management and director positions of new business start-ups and established multinational organizations with over 30 years of experience in the Security, Information Technology and Communications industries. With leadership skills in management of international operations, shareholder exit strategies, and overall business development, he has utilized a wide range of strategic programs to maximize organic growth into specific industry segments through OEM, alliances, and direct multi-level distribution channels.

Mr. Baldassarre is able to plan, organize and direct all aspects of a Corporation from Operations, P&L oversight, product distribution, Product promotions, sales and development activities and initiatives utilizing my extensive marketing/sales senior management experience with developed abilities in team leadership and program/campaign development. Directly involved in the growth, branding and ultimately optimizing market share, product awareness, revenues, profitability and shareholder value.

Mr. Baldassare is also the President of LRG Security Canada Inc. and LRG Security Europe.

Franco Staino

DIRECTOR

Mr. Franco Staino is a business professional with over 40 years experience in the pharmaceutical industry. Mr. Staino has significant experience in drug safety, traceability and anti-counterfeiting measures and has designed and implemented programs for the Italy National Health Service, the Ministry of Health and the Polygraphic Institute and State Mint.

Mr. Staino currently holds multiple positions including being the control representative of Carlucci a leading company engaged in the production of self-adhesive labels for consumer goods with high specialization for the pharmaceutical sector, and President of the Board of Directors of Topharmacia, a company that deals with the integral management of pharmacies throughout Italy in order to improve their ability to provide social and commercial services, to connect industrial marketing policy to that of the pharmacy, to offer tools in able to guarantee the financial balance of the companies involved.

Dr. Sazzad Hossain, PhD

Chief Scientific Officer

He is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company. Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada. Working with the Canadian government he helped establish the pharmacology laboratory to evaluate safety and efficacy of cannabinoid-based and other drugs under development for cancer, cardiovascular and ocular diseases.

Sina Pirooz

Director

Mr. Chatterton brings over 18 years of experience in development and execution of complex projects. His  expertise includes project management, facility management, logistics, and supply side processes and  procedures at a number of operations in Canada and internationally. He has  been involved in the public markets for the last three years managing IPO processes and transitioning  businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of  Canada’s Queens University with a Bachelor’s degree in Engineering Chemistry (2001) and Master’s degree in Chemical Process Engineering (2003).

Austin Thornberry

Director

Mr. Thornberry is a seasoned finance professional with a background in advising new companies in the venture capital market. He brings extensive experience working with high-growth companies across numerous industries through his past work in the technology and innovation banking group at the Bank of Montreal and in the financial services arm of Ernst & Young advising on multiple capital markets transactions. Mr. Thornberry has split his time working in Toronto, Ont., and Vancouver, B.C. He obtained his bachelor of commerce at McGill University and has held the CPA, CA, designation since 2019.

Matt Chatterton

DIRECTOR

Mr. Chatterton brings over 18 years of experience in development and execution of complex projects. His  expertise includes project management, facility management, logistics, and supply side processes and  procedures at a number of operations in Canada and internationally. He has  been involved in the public markets for the last three years managing IPO processes and transitioning  businesses to post listing operations. Mr. Chatterton is a Professional Engineer and graduate of  Canada’s Queens University with a Bachelor’s degree in Engineering Chemistry (2001) and Master’s degree in Chemical Process Engineering (2003).

Sign Up For News Alerts

Enter your details below and we will add you to our News Alerts list.

Consent(Required)

Jacob Moshinsky

Chief Operating Officer

Jacob is the CEO & founder of MoviWear a GPS, fall down detection & remote vital-sign monitoring platform, alerting caregivers of real-time emergencies. Jacob is a communications and technology expert with over 15 years’ experience in the field. the NurtureWatch health monitoring Smartwatch and MoviWearMED remote vital sign monitoring platform Prior to MoviWear, Jacob worked in both the Canadian telecom and the CPG industry. He led the Product Development and Business Strategy team at TELUS for the Small Business Portfolio. Jacob also worked in various product and service management roles within Rogers Communications where he launched and managed wireless and wireline products.